{"as_of":"2026-09-17T11:23:21.954Z","query":{"query.cond":"melanoma"},"count":20,"trials":[{"nct_id":"NCT01153763","title":"A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma","status":"COMPLETED","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"GlaxoSmithKline","enrollment":92,"start_date":"2010-08-09","completion_date":"2016-06-01","conditions":["Melanoma"],"url":"https://clinicaltrials.gov/study/NCT01153763"},{"nct_id":"NCT02065063","title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors","status":"COMPLETED","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"GlaxoSmithKline","enrollment":28,"start_date":"2014-04-22","completion_date":"2016-06-23","conditions":["Cancer"],"url":"https://clinicaltrials.gov/study/NCT02065063"},{"nct_id":"NCT03455764","title":"MCS110 With BRAF/MEK Inhibition in Patients With Melanoma","status":"COMPLETED","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Dana-Farber Cancer Institute","enrollment":6,"start_date":"2018-09-10","completion_date":"2023-09-05","conditions":["Melanoma"],"url":"https://clinicaltrials.gov/study/NCT03455764"},{"nct_id":"NCT01320085","title":"A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma","status":"COMPLETED","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Pfizer","enrollment":183,"start_date":"2011-03-24","completion_date":"2023-02-06","conditions":["BRAF or NRAS Mutant Metastatic Melanoma"],"url":"https://clinicaltrials.gov/study/NCT01320085"},{"nct_id":"NCT02872259","title":"BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma","status":"COMPLETED","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Haukeland University Hospital","enrollment":74,"start_date":"2017-02-13","completion_date":"2024-05-23","conditions":["Melanoma"],"url":"https://clinicaltrials.gov/study/NCT02872259"},{"nct_id":"NCT06703398","title":"A Study of GC101 TIL in Advanced Melanoma","status":"RECRUITING","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"Shanghai Juncell Therapeutics","enrollment":98,"start_date":"2024-12-20","completion_date":"2027-12-20","conditions":["Melanoma"],"url":"https://clinicaltrials.gov/study/NCT06703398"},{"nct_id":"NCT05984615","title":"Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients","status":"COMPLETED","phases":[],"study_type":"OBSERVATIONAL","lead_sponsor":"Novartis Pharmaceuticals","enrollment":1961,"start_date":"2022-06-08","completion_date":"2022-08-24","conditions":["BRAF Positive Metastatic Melanoma"],"url":"https://clinicaltrials.gov/study/NCT05984615"},{"nct_id":"NCT05859074","title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","status":"RECRUITING","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Memorial Sloan Kettering Cancer Center","enrollment":56,"start_date":"2023-05-04","completion_date":"2028-05-04","conditions":["Cutaneous Squamous Cell Carcinoma","SCC - Squamous Cell Carcinoma","Basal Cell Carcinoma","BCC","BCC - Basal Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Sebaceous Carcinoma","Extramammary Paget Disease","Kaposi Sarcoma","Head and Neck Squamous Cell Carcinoma","HNSCC","Adnexal Carcinoma","Angiosarcoma","Cutaneous Neoplasm","Advanced Cancer","Metastatic Cancer","Refractory Cancer","Solid Tumor"],"url":"https://clinicaltrials.gov/study/NCT05859074"},{"nct_id":"NCT02500576","title":"Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma","status":"COMPLETED","phases":["PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"M.D. Anderson Cancer Center","enrollment":18,"start_date":"2015-08-07","completion_date":"2022-10-12","conditions":["Metastatic Melanoma","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7"],"url":"https://clinicaltrials.gov/study/NCT02500576"},{"nct_id":"NCT02771340","title":"Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma","status":"COMPLETED","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Iconic Therapeutics, Inc.","enrollment":10,"start_date":"2016-05","completion_date":"2017-09","conditions":["Uveal Melanoma","Choroid Neoplasm"],"url":"https://clinicaltrials.gov/study/NCT02771340"},{"nct_id":"NCT00116597","title":"Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma","status":"COMPLETED","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","lead_sponsor":"University Hospital, Basel, Switzerland","enrollment":15,"start_date":"2002-11","completion_date":"2008-12","conditions":["Melanoma"],"url":"https://clinicaltrials.gov/study/NCT00116597"},{"nct_id":"NCT00005052","title":"Vaccine Therapy in Treating Patients With Primary Stage II Melanoma","status":"UNKNOWN","phases":["PHASE3"],"study_type":"INTERVENTIONAL","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","enrollment":null,"start_date":"1999-12","completion_date":null,"conditions":["Melanoma (Skin)"],"url":"https://clinicaltrials.gov/study/NCT00005052"},{"nct_id":"NCT01588847","title":"Anesthesia and Cancer Recurrence im Malignant Melanoma","status":"UNKNOWN","phases":["NA"],"study_type":"INTERVENTIONAL","lead_sponsor":"University Hospital Muenster","enrollment":230,"start_date":"2012-03","completion_date":"2019-03","conditions":["Malignant Melanoma"],"url":"https://clinicaltrials.gov/study/NCT01588847"},{"nct_id":"NCT06805825","title":"A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit","status":"RECRUITING","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Novelty Nobility, Inc.","enrollment":67,"start_date":"2025-02-03","completion_date":"2027-12-31","conditions":["Gastrointestinal Stromal Tumors","Small-cell Lung Cancer","Adenoid Cystic Carcinoma","Uveal Melanoma","Neuroendocrine Tumors","Chromophobe Renal Cell Carcinoma","Clear Cell Renal Cell Carcinoma"],"url":"https://clinicaltrials.gov/study/NCT06805825"},{"nct_id":"NCT06270706","title":"A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors","status":"RECRUITING","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Pliant Therapeutics, Inc.","enrollment":124,"start_date":"2023-08-30","completion_date":"2030-06","conditions":["Advanced or Metastatic Solid Tumor"],"url":"https://clinicaltrials.gov/study/NCT06270706"},{"nct_id":"NCT00701987","title":"Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma","status":"UNKNOWN","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Advanced Life Sciences, Inc.","enrollment":12,"start_date":"2008-06","completion_date":null,"conditions":["Melanoma"],"url":"https://clinicaltrials.gov/study/NCT00701987"},{"nct_id":"NCT00405587","title":"Safety Study of PLX4032 in Patients With Solid Tumors","status":"COMPLETED","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Plexxikon","enrollment":109,"start_date":"2006-11","completion_date":"2016-02","conditions":["Malignant Melanoma","Colorectal Carcinoma"],"url":"https://clinicaltrials.gov/study/NCT00405587"},{"nct_id":"NCT01841463","title":"Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation","status":"SUSPENDED","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Piramal Enterprises Limited","enrollment":100,"start_date":"2013-08","completion_date":"2016-03","conditions":["Advanced or Inoperable Malignant Melanoma With BRAF Mutation"],"url":"https://clinicaltrials.gov/study/NCT01841463"},{"nct_id":"NCT02203864","title":"Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma","status":"COMPLETED","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"Boehringer Ingelheim","enrollment":49,"start_date":"1998-08","completion_date":null,"conditions":["Melanoma"],"url":"https://clinicaltrials.gov/study/NCT02203864"},{"nct_id":"NCT03990493","title":"Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma","status":"UNKNOWN","phases":["PHASE1"],"study_type":"INTERVENTIONAL","lead_sponsor":"PrimeVax Immuno-Oncology Inc.","enrollment":10,"start_date":"2024-04-01","completion_date":"2024-12-31","conditions":["Advanced Melanoma"],"url":"https://clinicaltrials.gov/study/NCT03990493"}],"source":"Source: National Library of Medicine (ClinicalTrials.gov)","disclaimer":"Courtesy of the National Library of Medicine (ClinicalTrials.gov), retrieved at as_of; distributions and totals are computed by AnswerPool. Registry entries are submitted by sponsors and reflect what was registered, not verified outcomes. Not medical advice.","refresh_after":"2026-09-18T00:00:00.000Z"}